Despite convincing evidence of efficacy in metastatic disease from wild-type KRAS/BRAF colorectal tumors [9], including the finding of a high percentage of resectability of liver metastases following cetuximab-based systemic therapy [26], the addition of cetuximab to standard chemotherapy in patients with wild-type KRAS colon cancer failed to meet the endpoint of prolonged disease-free survival in a recently concluded randomized trial in the adjuvant setting [27]. Here, BRAF is linked to malignant colon neoplasm.